Inherited retinal diseases (IRDs) lead to the progressive death of photoreceptors in the retina. In cone-rod dystrophy (CORD) visual acuity and colour-discrimination are lost first, followed by dim light vision. Conversely, in retinitis pigmentosa (RP) dim light vision is initially compromised. No effective cure exists for RP and CORD except for gene therapy carried by viral vectors and limited to some specific forms of disease. We will design innovative nano-sized lipid vesicles and test their effectiveness as vehicles to deliver genes, small molecules or high amount of proteins with the potential to slow down or stop retinal degeneration. Vision loss remains one of the most dreaded diseases of the nervous system due to its dramatic impact on the quality of life of affected patients. Many early-onset forms of IRD are caused by inherited mutations in key genes involved in the light transduction process in photoreceptors, which lead to legal blindness and are currently incurable. Biocompatible lipid nanovesicles, which offer a variety of administration routes and low adverse effects, can contain high amounts of therapeutic genes, small molecules or proteins, and thus have great potential to improve the currently limited therapeutic options for both RP and CORD.